Neutralizing IGF-1 monoclonal antibody with cross-species reactivity.
We report the generation of a murine IGF-1 monoclonal antibody designated 35I17, which exhibits unique cross-species reactivity. The antibody recognizes recombinant human and rat IGF-1 in ELISA, Western blots, and in an 125I-recombinant human IGF-1 Scintillation Proximity Assay. In addition, 35I17 blocks cell proliferation induced by recombinant human and rat IGF-1, and inhibits cell proliferation induced by sera from human, rat, calf, dog, goat, or mouse. The antibody inhibits rat IGF-1 binding to IGF-1 receptors, and prevents IGF-1-stimulated receptor and IRS-1 phosphorylation in LISN C4 cells, an IGF-1 receptor-transfected cell line. The cross-species and neutralizing properties of 35I17 may be useful in in vitro and in vivo animal studies for elucidating the role of IGF-1 in cancer, rheumatoid arthritis, and other diseases.
Su
J L
JL
Department of Molecular Sciences, Glaxo Wellcome Research and Development, Research Triangle Park, NC 27709, USA.
Stimpson
S
S
Edwards
C
C
Van Arnold
J
J
Burgess
S
S
Lin
P
P
D016475:3T3 Cells / Q000187:drug effects; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000378:metabolism* / Q000494:pharmacology; D001667:Binding, Competitive; D002415:Cats; D002417:Cattle; D002455:Cell Division / Q000187:drug effects; D003429:Cross Reactions; D004285:Dogs; D006041:Goats; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D051381:Rats; D017526:Receptor, IGF Type 1 / Q000187:drug effects / Q000378:metabolism
D000911:Antibodies, Monoclonal; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1